Patent · US Active

Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes

US8722964B2 · kind B2 · utility

11Cited by
29References
34Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 23, 2010
Grant dateMay 13, 2014
Priority date
Expiry dateOct 22, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/90
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.